BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $17.52 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 6.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 472,288 shares of the biopharmaceutical company’s stock after purchasing an additional 26,773 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in PTC Therapeutics were worth $17,522,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. KBC Group NV grew its holdings in PTC Therapeutics by 29.2% during the third quarter. KBC Group NV now owns 2,232 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 504 shares during the period. CWM LLC raised its stake in PTC Therapeutics by 354.7% in the third quarter. CWM LLC now owns 2,687 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 2,096 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of PTC Therapeutics by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,782 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 492 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of PTC Therapeutics in the second quarter valued at approximately $128,000. Finally, Quarry LP boosted its stake in shares of PTC Therapeutics by 100.0% during the 2nd quarter. Quarry LP now owns 5,000 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 2,500 shares during the period.

PTC Therapeutics Price Performance

Shares of NASDAQ PTCT opened at $43.23 on Friday. The business has a fifty day moving average price of $39.30 and a two-hundred day moving average price of $35.81. The stock has a market capitalization of $3.33 billion, a PE ratio of -7.28 and a beta of 0.63. PTC Therapeutics, Inc. has a fifty-two week low of $20.75 and a fifty-two week high of $46.98.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on PTCT shares. Royal Bank of Canada raised their price target on PTC Therapeutics from $32.00 to $34.00 and gave the company a “sector perform” rating in a report on Friday, October 4th. Cantor Fitzgerald restated an “overweight” rating and set a $64.00 target price on shares of PTC Therapeutics in a research note on Tuesday, September 17th. UBS Group started coverage on shares of PTC Therapeutics in a research note on Monday, August 26th. They issued a “buy” rating and a $47.00 price target on the stock. Baird R W upgraded shares of PTC Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 4th. Finally, Barclays upped their target price on PTC Therapeutics from $31.00 to $43.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $42.00.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.